JP2020503841A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503841A5
JP2020503841A5 JP2019519313A JP2019519313A JP2020503841A5 JP 2020503841 A5 JP2020503841 A5 JP 2020503841A5 JP 2019519313 A JP2019519313 A JP 2019519313A JP 2019519313 A JP2019519313 A JP 2019519313A JP 2020503841 A5 JP2020503841 A5 JP 2020503841A5
Authority
JP
Japan
Prior art keywords
cell
disorder
disease
cells
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019519313A
Other languages
English (en)
Japanese (ja)
Other versions
JP7213799B2 (ja
JP2020503841A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2017/051133 external-priority patent/WO2018069927A1/en
Publication of JP2020503841A publication Critical patent/JP2020503841A/ja
Publication of JP2020503841A5 publication Critical patent/JP2020503841A5/ja
Application granted granted Critical
Publication of JP7213799B2 publication Critical patent/JP7213799B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019519313A 2016-10-10 2017-10-10 非細胞傷害性改変細胞およびその使用 Active JP7213799B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662406005P 2016-10-10 2016-10-10
US62/406,005 2016-10-10
PCT/IL2017/051133 WO2018069927A1 (en) 2016-10-10 2017-10-10 Non-cytotoxic modified cells and use thereof

Publications (3)

Publication Number Publication Date
JP2020503841A JP2020503841A (ja) 2020-02-06
JP2020503841A5 true JP2020503841A5 (https=) 2020-11-12
JP7213799B2 JP7213799B2 (ja) 2023-01-27

Family

ID=61906189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519313A Active JP7213799B2 (ja) 2016-10-10 2017-10-10 非細胞傷害性改変細胞およびその使用

Country Status (8)

Country Link
US (2) US12098202B2 (https=)
EP (1) EP3522936A4 (https=)
JP (1) JP7213799B2 (https=)
CN (1) CN110022907A (https=)
AU (1) AU2017342176A1 (https=)
CA (1) CA3039774A1 (https=)
IL (1) IL265962B2 (https=)
WO (1) WO2018069927A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514187A (ja) * 2018-02-15 2021-06-10 ザ ナショナル インスティテュート フォー バイオテクノロジー イン ザ ネゲヴ リミテッドＴｈｅ Ｎａｔｉｏｎａｌ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｉｎ Ｔｈｅ Ｎｅｇｅｖ Ｌｔｄ． キメラ抗原受容体の腫瘍環境特異的発現
EP3768707A4 (en) * 2018-03-19 2022-01-26 The Invention Science Fund II, LLC COMPOSITIONS AND METHODS FOR MODIFIED B CELLS EXPRESSING REALIZED BIOLOGICAL AGENTS
CN110357962B (zh) * 2018-07-06 2021-11-26 北京天成新脉生物技术有限公司 低adcc/cdc功能性单抗及其制备方法与应用
US12473361B2 (en) 2019-01-11 2025-11-18 The Wistar Institute Of Anatomy And Biology DNA monoclonal antibodies targeting PD-1 for the treatment and prevention of cancer
US20240424167A1 (en) * 2021-04-27 2024-12-26 Beijing Biosis Healing Biological Technology Co., Ltd. Chimeric peptide-modified sis membrane, preparation method therefor and application thereof
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
AU729377B2 (en) 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7427665B2 (en) 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
CA2599606A1 (en) * 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2006133164A2 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20100267145A1 (en) 2006-06-05 2010-10-21 Hiroshima University Immunocompetent cell having anti-cd38 antibody on its cell surface
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US10155038B2 (en) * 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
CA2712298C (en) * 2008-01-17 2015-11-24 Irm Llc Improved anti-trkb antibodies
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
US20100261776A1 (en) * 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
ES3063961T3 (en) * 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
TWI750110B (zh) * 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20170151281A1 (en) * 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN110699371A (zh) * 2016-03-18 2020-01-17 江苏普瑞康生物医药科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
CN109415698A (zh) * 2016-06-16 2019-03-01 斯隆－凯特林纪念癌症中心 工程化Treg细胞

Similar Documents

Publication Publication Date Title
JP2020503841A5 (https=)
JP7195400B2 (ja) 細胞内抗原に対して指向された単一ドメイン抗体
JP6901493B2 (ja) 抗ｂｃｍａポリペプチド及びタンパク質
Suzuki et al. Semaphorins and their receptors in immune cell interactions
US20220040298A1 (en) Use of vista agonists and antagonists to suppress or enhance humoral immunity
Stoiber et al. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3
US20220242974A1 (en) Anti-pd-l1 nanobody and fc fusion protein and application thereof
McDyer et al. IL-2 receptor blockade inhibits late, but not early, IFN-γ and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and-independent pathways of IFN-γ production
Zanetti et al. Expression and functional role of α7 nicotinic receptor in human cytokine-stimulated natural killer (NK) cells
CN110945120A (zh) 测量纳米药物中受体-配体相互作用的效力的测定
FI3303396T3 (fi) Vasta-aineita ox40:ää vastaan ja niiden käyttöjä
WO2016126781A4 (en) Tnfrsf-binding agents and uses thereof
IL258029B (en) Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
EP3687569A1 (en) Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
Mizui et al. Immune semaphorins: novel features of neural guidance molecules
FI3443010T3 (fi) Uusia anti-sirp -vasta-aineita ja niiden terapeuttisia sovelluksia
Mahesh et al. Expression of GITR ligand abrogates immunosuppressive function of ocular tissue and differentially modulates inflammatory cytokines and chemokines
Kamimura et al. The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity
Senthilkumar et al. CD137L-and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation
Volkov et al. The impact of the intracellular domains of chimeric antigenic receptors on the properties of CAR T-cells
Giraldo et al. New targets in systemic lupus (part 2/2)
Paul et al. Characterisation of monoclonal antibodies to the TNF and TNF receptor families
Sun et al. Research Note: Development and characterization of monoclonal antibodies specific for chicken interleukin-7 receptor α (CD127)
KR20170031126A (ko) 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법
Bhavesh CD4+ T Cell-derived Novel Peptide Thp5 Induces Interleukin-4 Production in CD4+ T Cells to Direct T Helper 2 Cell Differentiation